Demographic and laboratory values, by study group and study time
| Cirrhosis | Post-LT | |||||
| T1 (n=10) | T2 (n=6) | T3 (n=5) | T1 (n=12) | T2 (n=10) | T3 (n=7) | |
| Age | 65.2±11.6 | 55.1±6.6* | ||||
| Male/female | 4/6 | 9/3 | ||||
| Education (years) | 9.6±4.7 | 9.6±2.7 | ||||
| INR | 1.1±0.2 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.1±0.1 | 1.1±0.1 |
| Albumin (g/dL) | 3.6±0.4 | 3.6±0.3 | 3.5±0.3 | 3.5±0.1 | 3.5±0.1 | 3.5±0.1 |
| Total bilirubin (μmol/L) | 25.0±21.8 | 12.2±8.9 | 11.0±4.2 | 17.9±9.3 | 14.2±9.0 | 16.0±8.1 |
| Creatinine (μmol/L) | 73.0±13.9 | 69.5±16.5 | 85.1±25.8 | 76.8±15.0 | 83.7±18.0 | 84.7±33.5 |
| Ammonia (μmol/L) | 29±22 | 21±9 | 16±11 | 31±36 | 22±17 | 33±22 |
| Child class | All A | All A | All A | NA | ||
| MELD | 9±3 | 7±1 | 8±1 | NA | ||
| Fibrosis (kPa) | NA | NA | NA | 13.2±6.0 (n=12) | 7.1±1.7 (n=10) | 10 (n=1) |
| Genotype 1/2/3/4 | 6/3/0/1 | 8/0/3/1 | ||||
| Comorbidities (treated) | 2/10 Diabetes 2/10 Hypothyroidism | 2/12 Diabetes | ||||
| HCV-RNA+ (n/total n) | 10/10 | 1/10 | 2/10 | 12/12 | 0/12 | 0/12 |
| HCV-RNA (UI/mL) | 1 807 755±1 892 805 | 1 731 839 | 822 624±1 127 659 | 7 661 900±13 906 807 | NA | NA |
*P<0.05.
HCV, hepatitis C virus; LT, liver transplant; NA, not available; INR, international normalised ratio; MELD, model for end-stage liver disease.